Drugs / QLM3003
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05932888 | Jun → Aug 2023 | atopic eczema | Qilu Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06058000 | Nov 2023 → Sep 2024 | atopic eczema | Qilu Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06880276 | May 2025 → Mar 2027 expected | atopic eczema | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QLM3003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06880276 ↗ |
| Route | Topical | “QLM3003 topical cream” NCT06058000 ↗ |